Martínez, C., Khvedelidze, I., Fekom, M., Deau Fischer, B., Marouf, A., Ghesquières, H., . . . Sureda, A. (2025). Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group. Bone Marrow Transplantation: Official journal of the European Society for Blood and Marrow Transplantation, 60(6), 879. https://doi.org/10.1038/s41409-025-02568-4
Chicago-referens (17:e uppl.)Martínez, Carmen, et al. "Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) as Maintenance Therapy After ASCT According to Previous Exposure to BV. A Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group." Bone Marrow Transplantation: Official Journal of the European Society for Blood and Marrow Transplantation 60, no. 6 (2025): 879. https://doi.org/10.1038/s41409-025-02568-4.
MLA-referens (9:e uppl.)Martínez, Carmen, et al. "Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) as Maintenance Therapy After ASCT According to Previous Exposure to BV. A Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group." Bone Marrow Transplantation: Official Journal of the European Society for Blood and Marrow Transplantation, vol. 60, no. 6, 2025, p. 879, https://doi.org/10.1038/s41409-025-02568-4.
